Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time (Q35558566)

8 August 2017

1 reference

title

Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

1

Ioannidis JP

1 reference

8 August 2017

Polycarpou A

2

1 reference

PubMed ID

14556918

8 August 2017

Ntais C

series ordinal

3

1 reference

PubMed ID

14556918

8 August 2017

Pavlidis N

series ordinal

4

1 reference

8 August 2017

1 November 2003

1 reference

European Journal of Cancer

8 August 2017

1 reference

8 August 2017

39

1 reference

8 August 2017

16

1 reference

8 August 2017

2278-2287

1 reference

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

The taxanes: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Chemotherapy of Advanced Non-Small-Cell Lung Cancer with Cyclophosphamide, Adriamycin, Methotrexate, and Procarbazine versus Cisplatin and Etoposide A Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

The impact of high-risk patients on the results of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Can quality of clinical trials and meta-analyses be quantified?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Practical problems in interim analyses, with particular regard to estimation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Use of spending functions for occasional or continuous monitoring of data in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Language bias in randomised controlled trials published in English and German.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

The existence of publication bias and risk factors for its occurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Levels of absolute survival benefit for systemic therapies of advanced cancer. a call for standards

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

1 reference

7 January 2021

Why do we need some large, simple randomized trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Summing up evidence: one answer is not always enough.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Individual patient data meta-analysis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

Call for a new approach to the process of clinical trials and drug registration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900571-9

7 January 2021

10.1016/S0959-8049(03)00571-9

Identifiers

DOI

1 reference

8 August 2017

1 reference

PubMed ID

14556918